News and Events
Rostock, April 7, 2011
On March 29, 2011 a symposium on real-time cell analysis was held in Rostock, Germany. Prof. Dr. Markus Tiedge of the Institute of Medical Biochemistry and Molecular Biology, University Rostock, hosted the Bionas Symposium on real-time cell analysis. In his welcome speech, Prof. Tiedge emphasized the advantages and the importance of scientific progress from the Bionas DiscoveryTM 2500 system.
About thirty scientists from Rostock, Berlin, Munich and Aachen participated at the conference. Dr. Ralf Ehret, CEO and President of Bionas GmbH, introduced the new Bionas DiscoveryTM adcon reader and its applications.
Prof. Stefan Wölfl from the Institute of Pharmacy and Molecular Biotechnology, University of Heidelberg, presented results on the topic Online monitoring of drug response in cancer cell lines´. He emphasized the advantages of real-time data acquisition with the Bionas DiscoveryTM 2500 system, i.e. the O2-consumption, the extracellular acidification and impedance. The Bionas DiscoveryTM 2500 system not only delivers new insights into cellular behavior in response to drug candidates, but also serves to optimize the concerted use of other methods in the research lab.
PD Dr. Jörg Andrä from the Research Center Borstel at the Leibniz-Center for Medicine and Biosciences covered the development of peptide-based cancer drugs and how the Bionas DiscoveryTM 1500 system reveals peptide specific effects on cell morphology and metabolism in cancer cells.
Following said presentations, Dr. Stefanie Ortinau, Vice President R&D at Bionas GmbH, demonstrated the new Bionas DiscoveryTM adcon reader application on real-time monitoring of endogenous GPCR signaling.
About Bionas GmbH
Bionas GmbH, based in Rostock/Germany, is provider of instruments and services for real-time and label-free cell assays: The Bionas DiscoveryTM 2500 system - analysis of bioenergetics (glycolysis, mitochondrial respiration) and cell impedance/adhesion, and the Bionas DiscoveryTM adcon reader for analysis of cell impedance/adhesion in multi-well format.
Application fields include: toxicology, oncology, mitochondrial research, receptor signalling (e.g. GPCR assays) and drug profiling, cell culture optimization, quality control of cells.
Our laboratories are GLP certified laboratories and suited for contract research.
Bionas GmbH and Biozym Scientific GmbH join forces for sales activities in Germany and Austria
Rostock, den 4. März 2011
Vertriebskooperation Bionas Biozym
Die Biozym Scientific GmbH und Bionas GmbH vereinbaren eine Vertriebskooperation für die Produkte und Analysesysteme der Bionas GmbH.
Das Bionas DiscoveryTM 2500 system zur Aufzeichnung der metabolischen Parameter, Respiration und Ansäuerungsrate, sowie der zellulären Impedanz in real-time und der Bionas DiscoveryTM adcon reader, zum real-time Monitoring von zellulärer Impedanz im 96 well Format, werden nun auch über Biozym in Deutschland und Österreich angeboten. Bionas begrüßt außerordentlich die vereinbarte Kooperation mit dem neuen Partner, der seit 25 Jahren erfolgreich im deutschsprachigen Life Science Markt agiert.
Biozym Scientific erweitert damit ihr bestehendes Portfolio, um auch dem Forscher im Zellkulturlabor innovative High-Tech Geräte anbieten zu können. Biozym und Bionas folgen damit dem verstärkten Trend zu markierungsfreien, real-time Assays in der zellbiologischen Forschung.
Über Biozym Scientific GmbH:
Die Biozym Scientific GmbH mit Sitz in Hessisch Oldendorf bietet seit 25 Jahren als eigenständige und leistungsorientierte Vertriebs- und Serviceorganisation anspruchsvolle Lösungen für den Life Science-Markt in Deutschland, Österreich und weiteren europäischen Ländern an. Das Produktportfolio umfasst hochwertige Kunststoff- Verbrauchsmaterialien für den täglichen Laborbedarf, Feinchemikalien, Kits und High- Tech Gerätesysteme für die Molekularbiologie sowie speziell angepasste Servicedienstleistungen.
www.biozym.com
Über Bionas GmbH:
Bionas GmbH, Rostock, ist Hersteller von Analysensystemen für markierungsfreie, zellbasierte Assays in Echtzeit mit Anwendungen in pre-klinischer Substanzevaluierung, Toxikologie, Zellkulturoptimierung, onkologische Forschung, Regenerative Medizin. Neben Instrumenten und Verbrauchsmaterial bietet die Bionas GmbH Servicedienstleistungen im Bereich markierungsfreie Assays an.
www.bionas-discovery.com
Real time metabolic monitoring for time resolved analysis of the cellular drug response
Author: Prof. Stefan Wölfl
Date: Wednesday, November 9, 2011
Time: 10:30 AM - 11:30 AM EST [16:30 - 17:30 CET]
Biological activity of potential drug candidates and other biological active molecules in tissue culture is not a simple process, which depending on cell type and drug concentration, leads to a single specific drug response.
Cellular response to drug treatment is rather a complex event that includes immediate as well as delayed effects. In order to monitor drug activity in vitro, selected cell lines are treated with the compound under investigation and the cellular response is assayed only at selected time points, providing information on proliferation, viability or - on a molecular level - signal transduction and gene expression.
Real time metabolic monitoring using biosensor chips provides a simple approach to follow the time scale of the cellular response. This is possible, because independent of specific drug targets, drug treatment leads to perturbation of the cellular system and requires an adjustment of the basic metabolic activity of cells. The metabolic changes, namely glycolysis and respiration, as well as cell adhesion and cell-cell interaction can be continuously monitored with the BIONAS biosensor chip system. The biological activity of possible anti-cancer drugs and a wide range of other compounds will be studied in real time in various tissue culture models.
About the presenter:
Stefan Wölfl studied Pharmaceutical Sciences and obtained his PhD in Biochemistry (1990) at the Free University Berlin, Germany. After working as postdoc with Alexander Rich at MIT, Cambridge (USA), he assumed a position as junior group leader and established his own research group in
His research interests are in chip technologies for diagnostic applications; cellular biosensors for drug testing and environmental analysis, target identification; gene regulation in mammalian cells in disease models, influence of biochemical processes on DNA-damage and stress response.